Figure S8 from Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer

Key Points

• The treatment strategy shows improved outcomes in pancreatic cancer models with MTAP deletion and KRAS mutations.
• Utilizing the combination of PRMT5 inhibitors and KRAS inhibitors demonstrates a significant effect on cell viability.
• GSEA analysis reveals changes in cell signaling pathways when treated with PRMT5 inhibitors and KRAS inhibitors.
• These findings may enhance therapeutic approaches for difficult-to-treat pancreatic cancer cases.

Abstract